Selection of Lead Compounds Sample Clauses

Selection of Lead Compounds. Based on criteria to be determined by the JSC, the JSC may select Lead Compounds during the Screening Phase, the Screening Phase Tail or the Research Phase from (a) Hits in the ViroPharma Chemical Library, the Wyeth Chemical Library or any other library the Parties shall mutually agree to screen in connection with the Research Program, and/or (b) any Derivative of any such Hits.
Sample 1
AutoNDA by SimpleDocs
Selection of Lead Compounds. During the COLLABORATION TERM, * ALLERGAN shall have the right to select up to * compounds (one of which shall initially be 2-METHOXYESTRADIOL) from ENTREMED's library of compounds disclosed under Section 3.2 above, that appear promising for pre-clinical evaluation by ALLERGAN for use in the FIELD for designation as LEAD COMPOUNDS. From time to time thereafter, ALLERGAN may designate additional compounds as LEAD COMPOUNDS or remove the designation from previously designated LEAD COMPOUNDS so long as the total number of LEAD COMPOUNDS shall not exceed * at any time. A LEAD COMPOUND shall cease to be a LEAD COMPOUND, if it has not been designated as an ALLERGAN DESIGNATED COMMERCIAL COMPOUND in accordance with Section 3.9, within one (1) year following the termination of the COLLABORATION TERM.
Sample 1
Selection of Lead Compounds. Following the identification of a Compound, the further optimization and characterization of such Compound and the collection of data on such Compound, the Research Management Committee shall determine whether such Compound satisfies the Preclinical Development Criteria. The Research Management Committee shall notify Roche Bioscience in writing when a Compound is determined to have satisfied the Preclinical Development Criteria (the "RMC Notice"). Roche Bioscience shall have a 90-day period beginning on the date of the RMC Notice in which to select such Compound for development by providing written notice of such election to Alanex. If Roche Bioscience selects such Compound, the Compound will then be considered a Lead Compound for purposes of this Agreement and Roche Bioscience shall have the exclusive license to such Lead Compound, its analogues, all structurally-related compounds, and progenitors of the Lead Compound back to and including the predecessor Compound, as contemplated by Section 7.2. If Roche Bioscience does not select such Compound and if Roche Bioscience is not developing a structurally-related compound on which Roche Bioscience will be paying Milestones and Royalties under this Agreement, Alanex shall retain all rights to such Compound; provided, however, that Alanex cannot conduct any research with respect to or sublicense such Compound in the Field until termination of this Collaboration. If Roche
Sample 1
Selection of Lead Compounds. FG shall consult with Astellas with respect to Lead Compound selection, and shall provide to Astellas information as reasonably necessary to evaluate Lead Compound candidates in connection with the Lead Compound selection process, including without limitation the information relating to patent situations in the Astellas Territory. For the avoidance of doubt, such Lead Compound candidates shall potentially include any and all compounds Controlled by FG during the term hereof for use in the Field. Notwithstanding anything contained in this Agreement, FG shall designate, at its sole discretion but in line with the basic policy that the same Lead Compound shall be Commercialized both in Astellas Territory and FG Territory for the same Indication(s), Lead Compound(s) in accordance with the terms of this Section 4.3, and shall notify the JDC of such designations. At any one time, FG may designate up to two (2) Lead Compounds for Commercialization in any Indication; provided, that in the event that FG designates two (2) Lead [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Compounds for Commercialization in an Indication, it shall designate one (1) as the primary Lead Compound and one (1) as the secondary Lead Compound. In the event FG determines to cease development of a primary Lead Compound in an Indication, FG may designate the secondary Lead Compound as the primary Lead Compound for such Indication. In the event, prior to Marketing Approval in the Astellas Territory, FG determines to stop development of a Lead Compound, FG shall notify the JDC, and upon such notification, such compound shall no longer be considered a Lead Compound; provided, however, that Astellas may complete those development activities on-going at the time of such notification for such Lead Compound for a reasonable period of time, unless such notification is based on safety concerns. In the event FG determines to [ * ], FG shall [ * ] within [ * ] days of such [ * ]. In the event that FG [ * ], Astellas may, subject to the [ * ], [ * ], provided, however, that the [ * ] shall apply upon the [ * ] set forth in such Sections, rather than the [ * ].
Sample 1
Selection of Lead Compounds. During the COLLABORATION TERM, and for a period of * following the termination thereof, ALLERGAN shall have the right to select up to * compounds (one of which shall initially be 2-METHOXYESTRADIOL) from ENTREMED's library of compounds disclosed under Section 3.2 above, that appear promising for pre-clinical evaluation by ALLERGAN for use in the FIELD for designation as LEAD COMPOUNDS. From time to time thereafter, ALLERGAN may designate additional compounds as LEAD COMPOUNDS or remove the designation from previously designated LEAD COMPOUNDS so long as the total number of LEAD COMPOUNDS shall not exceed * at any time. A LEAD COMPOUND shall cease to be a LEAD COMPOUND, if it has not been designated as an ALLERGAN DESIGNATED COMMERCIAL COMPOUND in accordance with Section 3.9, within one (1) year following the termination of the COLLABORATION TERM.
Sample 1

Related to Selection of Lead Compounds

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Selection Criteria Each Contract is secured by a new or used Motorcycle. No Contract has a Contract Rate less than 1.00%. Each Contract amortizes the amount financed over an original term no greater than 84 months (excluding periods of deferral of first payment). Each Contract has a Principal Balance of at least $500.00 as of the Cutoff Date.

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

Time is Money Join Law Insider Premium to draft better contracts faster.